Abstract Number: 1079 • 2017 ACR/ARHP Annual Meeting
Treat to Target Adherence Measurement Tool Performance in Rheumatoid Arthritis
Background/Purpose: The purpose of the T2T approach in RA is to achieve remission or LDA according to results from objective activity measurements. This strategy has…Abstract Number: 1333 • 2017 ACR/ARHP Annual Meeting
Mortality of Tumor Necrosis Factor Transgenic Arthritic Mice with Interstitial Lung Disease Occurs with Pulmonary Arteriole Thickening and Right Ventricular Hypertrophy but Is Not Associated with Inducible Nitric Oxide Synthase Dependent Inflammatory Cell Infiltration
Background/Purpose: Rheumatoid arthritis associated interstitial lung disease (RA-ILD) occurs in up to 15% of RA patients, whose median survival expectancy after diagnosis is only 2.6…Abstract Number: 1349 • 2017 ACR/ARHP Annual Meeting
Treat to Target: What’s the Target?
Background/Purpose: The 2015 ACR RA treatment guidelines focus on measuring disease activity and provide a guideline driven treat to target strategy. We hope to understand…Abstract Number: 1418 • 2017 ACR/ARHP Annual Meeting
The Value of Adalimumab Trough Levels and Clinical Assessments in Predicting Clinical Response in Patients with Established Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Background/Purpose: Low trough levels of the tumor necrosis factor inhibitor, adalimumab (ADL), and anti-ADL antibodies (AAA) were reported to be correlated with lack of response…Abstract Number: 1425 • 2017 ACR/ARHP Annual Meeting
Treatment Patterns in Patients with Rheumatoid Arthritis Newly Initiated on Biologic and Non-Biologic Therapy Enrolled in a North American Clinical Registry
Background/Purpose: Many treatment options are currently available to patients with rheumatoid arthritis (RA), including tumor necrosis factor inhibitors (TNFi’s). While combination therapy of TNFi’s or…Abstract Number: 1703 • 2017 ACR/ARHP Annual Meeting
A Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation, Multi-Center Study of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells in Patients with Rheumatoid Arthritis and Incomplete Response to at Least One Tnfα Inhibitor
Background/Purpose: Allogeneic STRO-3 immunoselected mesenchymal precursor cells (MPCs) derived from bone marrow of healthy donors are a potent, homogeneous cell population which can be activated…Abstract Number: 353 • 2017 ACR/ARHP Annual Meeting
Patient Experiences of Rheumatoid Arthritis Models of Care: An International Survey
Background/Purpose: Despite the global prevalence of rheumatoid arthritis (RA), there is no single model of care (MoC) and little is known about the RA patient…Abstract Number: 1736 • 2017 ACR/ARHP Annual Meeting
Deep Immunophenotyping of T-Lymphocytes with a 37-Channel Mass Cytometry (CyTOF) Panel for the Identification of Pathological Cell Functions and the Prediction of Response to Biologic Drugs in Rheumatoid Arthritis
Background/Purpose: Pathogenic immune cell types and functions have not been identified yet in rheumatoid arthritis (RA). This is explained by the impact of disease heterogeneity…Abstract Number: 363 • 2017 ACR/ARHP Annual Meeting
Work Productivity Benefit in Patients with Rheumatoid Arthritis Initiating Etanercept in the United States
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that can progress to joint destruction, functional impairment and disability that can lead to work productivity…Abstract Number: 1904 • 2017 ACR/ARHP Annual Meeting
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Upadacitinib (ABT-494), a Selective JAK-1 Inhibitor, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Conventional Synthetic Dmards
Background/Purpose: Upadacitinib (UPA) is an oral, selective JAK-1 inhibitor in development for the treatment of patients (pts) with moderate to severe rheumatoid arthritis (RA) and…Abstract Number: 427 • 2017 ACR/ARHP Annual Meeting
Do We Treat Men and Women Differently, and Is This a Good Thing?
Background/Purpose: Men seem to respond better to antirheumatic treatment than women with RA. In daily practice, expectations towards responsiveness may influence rheumatologists when making treatment…Abstract Number: 2242 • 2017 ACR/ARHP Annual Meeting
Pattern and Influential Factors in Promoting Treat-to-Target (T2T) for Follow-up RA Patients with a Rheumatologist-Patient Interactive Smart System of Disease Management (SSDM): A Cohort Study from China
Background/Purpose: Treat-to-Target (T2T), achieving a DAS28 lower than 2.6 (remission) or below 3.2 (low disease activity), is the main management strategy. The Smart System of…Abstract Number: 439 • 2017 ACR/ARHP Annual Meeting
Analysis of Rheumatoid Arthritis Patients That Did Not Achieve the Treatment Goal By the Treat-to-Target Strategy in Daily Practice
Background/Purpose: Although the goal of rheumatoid arthritis (RA) treatment is to achieve remission or low disease activity with the treat-to-target (T2T) strategy, some patients do…Abstract Number: 2438 • 2017 ACR/ARHP Annual Meeting
Open Label Transitioning from Originator Etanercept to Biosimilar SB4 Compared to Continuing Treatment with Originator Etanercept in a Historical Cohort in Rheumatic Diseases in Daily Practice
Background/Purpose: Blinded transitioning from originator infliximab (INX) to biosimilar CT-P13 was not inferior to continuing INX treatment.1 Open label mandatory transitioning resulted in a slightly…Abstract Number: 449 • 2017 ACR/ARHP Annual Meeting
Medical Bugs for Pain Relief in Patients with Rheumatoid Arthritis, a Systematic Review
Background/Purpose: Medical bugs, a term used to describe insects and arthropods for medical treatment, have been widely used in the past centuries for pain relief.…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 10
- Next Page »